Ivosidenib Confers BRCAness Phenotype and Synthetic Lethality to Poly (ADP-Ribose) Polymerase Inhibition in <i>BRCA1/2</i>-Proficient Cancer Cells

Ivosidenib Confers BRCAness Phenotype and Synthetic Lethality to Poly (ADP-Ribose) Polymerase Inhibition in <i>BRCA1/2</i>-Proficient Cancer Cells

<b>Background/Objectives</b>: PARP inhibitors (PARPi) are pivotal to treating homologous recombination repair-deficient (HRD) cancers, particularly <i>BRCA1/2</i>-mutated ovarian and breast cancers. However, most ovarian and breast cancers harbor wild-type (WT) <i>BRCA1...

Full description

Saved in:
Bibliographic Details
Main Authors: Danyang Zhou, Wei Liu, Yanyan Zhang, Chong Li
Format: Article
Language:English
Published: MDPI AG 2025-04-01
Series:Biomedicines
Subjects:
PARP inhibitors
ovarian cancer
HR repair
Ivosidenib
BRCA1/2
Online Access:https://www.mdpi.com/2227-9059/13/4/958
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items